The Pleiotropic Effects of SGLT2 Inhibitors: Remodeling the Treatment of Heart Failure
- PMID: 33478648
- DOI: 10.1016/j.jacc.2020.11.029
The Pleiotropic Effects of SGLT2 Inhibitors: Remodeling the Treatment of Heart Failure
Keywords: LV remodeling; SGLT2 inhibitors; cardiac magnetic resonance; clinical trial; heart failure.
Conflict of interest statement
Author Disclosures Dr. Goldberg has received research grants and consulting fees from Respircardia; and has received consulting fees from Abbott.
Comment on
-
Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction.J Am Coll Cardiol. 2021 Jan 26;77(3):243-255. doi: 10.1016/j.jacc.2020.11.008. Epub 2020 Nov 13. J Am Coll Cardiol. 2021. PMID: 33197559 Clinical Trial.
Similar articles
-
Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics.J Am Coll Cardiol. 2019 Apr 23;73(15):1931-1944. doi: 10.1016/j.jacc.2019.01.056. J Am Coll Cardiol. 2019. PMID: 30999996
-
Cardiac remodeling with SGLT2 inhibitors in heart failure with reduced ejection fraction.Minerva Cardiol Angiol. 2024 Feb;72(1):95-97. doi: 10.23736/S2724-5683.22.06207-X. Epub 2023 Jun 13. Minerva Cardiol Angiol. 2024. PMID: 37310155 No abstract available.
-
Potential Therapeutic Effects of Sodium Glucose-linked Cotransporter 2 Inhibitors in Stroke.Clin Ther. 2020 Nov;42(11):e242-e249. doi: 10.1016/j.clinthera.2020.09.008. Epub 2020 Sep 29. Clin Ther. 2020. PMID: 33008610 Review.
-
Meta-analysis of the effects of four factors on the efficacy of SGLT2 inhibitors in patients with HFrEF.ESC Heart Fail. 2021 Apr;8(2):1722-1724. doi: 10.1002/ehf2.13241. Epub 2021 Feb 5. ESC Heart Fail. 2021. PMID: 33544420 Free PMC article. No abstract available.
-
Do sodium-glucose co-transporter-2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis.Diabetes Obes Metab. 2018 Jun;20(6):1361-1366. doi: 10.1111/dom.13229. Epub 2018 Feb 20. Diabetes Obes Metab. 2018. PMID: 29359851 Review.
Cited by
-
Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors, anti-diabetic drugs in heart failure and cognitive impairment: potential mechanisms of the protective effects.Front Pharmacol. 2024 Jun 14;15:1422740. doi: 10.3389/fphar.2024.1422740. eCollection 2024. Front Pharmacol. 2024. PMID: 38948473 Free PMC article. Review.
-
Hypertensive Heart Failure.J Clin Med. 2023 Aug 2;12(15):5090. doi: 10.3390/jcm12155090. J Clin Med. 2023. PMID: 37568493 Free PMC article. Review.
-
Safety profile of sodium glucose co-transporter 2 (SGLT2) inhibitors: A brief summary.Front Cardiovasc Med. 2022 Sep 21;9:1010693. doi: 10.3389/fcvm.2022.1010693. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 36211584 Free PMC article. Review.
-
Pharmacological Anti-Remodelling Effects of Disease-Modifying Drugs in Heart Failure with Reduced Ejection Fraction.Clin Drug Investig. 2022 Jul;42(7):567-579. doi: 10.1007/s40261-022-01166-2. Epub 2022 Jun 20. Clin Drug Investig. 2022. PMID: 35726047 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
